朱丽丽,博士,副教授,硕士生导师

研究方向:
主要研究方向为化学生物学和结构生物学研究。包括基于靶标的药物筛选、与疾病有关靶标的结构、药物作用机制研究及基于结构生物学的创新药物设计。
简历:
2008年7月毕业于中科院福建物质结构研究所获博士学位
2008年8月至2011年7月在德国吕贝克大学生物化学系做博士后研究,研究内容:抗病毒药物筛选及病毒重要靶标的结构生物学研究
2011年8月至今在华东理工大学药学院任副教授,研究内容:1. 药物筛选和新药发现; 2. 药物靶标确证; 3. 生物芯片研制及应用
联系方式:
电话:021-64253379. email:zhulfl@ecust.edu.cn
所获荣誉:
u 2012年校首批优秀青年教师培育计划
u 2015年校优秀青年教师培育跟踪计划
u 2019年校青年英才培育计划
代表性研究成果:
10篇代表性期刊论文
1) Lili Zhu; Lei Shan; Junsheng Zhu; Li Li; Shiliang Li; Liyan Wang; Jiawei Wang; Shoude Zhang; Hongchang Zhou; Weidong Zhang; Honglin Li; Discovery of a natural fluorescent probe targeting the Plasmodium falciparum cysteine protease falcipain-2, SCIENCE CHINA Life Sciences, 2020, 63: 1016-1025 (第一作者,IF=6.036)
2) Guozhen Wu#; Lili Zhu#; Xing Yuan; Hao Chen; Rui Xiong; Shoude Zhang; Hao Cheng; Yunheng Shen; Huazhang An; Tiejun Li; Honglin Li; Weidong Zhang ; Britanin Ameliorates Cerebral Ischemia-Reperfusion Injury by Inducing the Nrf2 Protective Pathway, ANTIOXIDANTS & REDOX SIGNALING, 2017, 27(11): 754-768 (第一作者,IF=8.401)
3) Yi Tong; Qian Jiao; Yuanru Liu; Jiankun Lv; Rui Wang; Lili Zhu; Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats, Frontiers in Pharmacology, 2018, 9: 0-1032 (通讯作者,IF=5.811)
4) Jiawei Wang; Yanyan Diao; Junsheng Zhu; Shiliang Li; Zhenjiang Zhao; Honglin Li; Lili Zhu ; Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase, Medchemcomm, 2016, 7(5): 853-858 (通讯作者,IF=3.597)
5) Fangshu Wu; Junsheng Zhu; Honglin Li; Lili Zhu; Structural analysis of recombinant human ubiquitin-conjugating enzymeUbcH5c, Acta Pharmaceutica Sinica B, 2017, 7(3): 390-394 (通讯作者,IF=11.614)
6) Junsheng Zhu; Le Han; Yanyan Diao; Xiaoli Ren; Minghao Xu; Liuxin Xu; Shiliang Li; Qiang Li; Dong Dong; Jin Huang; Xiaofeng Liu; Zhenjiang Zhao; Rui Wang; Lili Zhu*; Yufang Xu*; Xuhong Qian*; Honglin Li*;Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase, Journal of Medicinal Chemistry, 2015, 58:1123−1139 (通讯作者,IF=7.446)
7) Minghao Xu; Junsheng Zhu; Yanyan Diao; Hongchang Zhou; Xiaoli Ren; Deheng Sun; Jin Huang; Dongmei Han; Zhenjiang Zhao; Lili Zhu*; Yufang Xu*; Honglin Li*; Novel Selective and Potent Inhibitors of Malaria Parasite Dihydroorotate Dehydrogenase: Discovery and Optimization of Dihydrothiophenone Derivatives, Journal of Medicinal Chemistry, 2013, 56: 7911−7924 (通讯作者,IF=7.446)
8) Fanxun Zeng; Shiliang Li; Guantian Yang; Yating Luo; Tiantian Qi; Yingfan Liang; Tingyuan Yang; Letian Zhang; Rui Wang; Lili Zhu*; Honglin Li*; Xiaoyong Xu*; Design, synthesis, molecular modeling, and biological evaluation of acrylamide derivatives as potent inhibitors of human dihydroorotate dehydrogenase for the treatment of rheumatoid arthritis, Acta Pharmaceutica Sinica B, 2021,11:795-809 (通讯作者,IF=11.614)
9) Pengxuan Ren; Weijuan Shang; Wanchao Yin; Huan Ge; Lin Wang; Xianglei Zhang; Bingqian Li; Honglin Li; Yechun Xu; Eric H. Xu; Hualiang Jiang; Lili Zhu*; Leike Zhang*; Fang Bai*; A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors, Acta pharmacologica Sinica, 2022;43(2):483-493 (通讯作者,IF=6.15)
10) Lin Wang, Yan Wu, Sheng Yao, Huan Ge, Ya Zhu, Kun Chen, Wenzhang Chen, Yi Zhang, Wei Zhu, Hong-yang Wang, Yu Guo, Peixiang Ma, Peng-xuan Ren, Xiang-lei Zhang, Huiqiong Li, Mohammad A. Ali, Wenqing Xu, Hua-liang Jiang, Leike Zhang, Lili Zhu*, Yang Ye*, Weijuan Shang*, Fang Bai*;Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Acta pharmacologica Sinica, 2021;1-9 (通讯作者,IF=6.15)
专利
u 授权专利:ZL 2012 80048338.3;ZL201510319723.2; ZL201810075170.4